CheckMate 73L, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 73L

A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225245

Enrollment

888

Registered

2020-06-25

Start date

2020-09-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Interventions

Arm A: Nivolumab + CCRT followed by nivolumab + ipilimumab maintenance Arm B: Nivolumab + CCRT followed by nivolumab maintenance Arm C: CCRT followed by durvalumab maintenance

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Eastern Cooperative Oncology Group (ECOG) performance status <=1 -Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) histologically-confirmed NSCLC, according to 8th TNM classification -Newly diagnosed and treatment-naive, with no prior local or systemic anticancer therapy given as primary therapy for locally advanced disease

Exclusion criteria

Exclusion criteria: -Active infection requiring systemic therapy within 14 days prior to randomization -History of organ or tissue transplant that requires systemic use of immune suppressive agents -Prior thoracic radiotherapy

Design outcomes

Primary

Measure	Time frame
PFS	—

Secondary

Measure	Time frame
PFS,OS,ORR,DoR,TTR	—

Countries

Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States

Contacts

Public ContactRaheel Nathani

Bristol-Myers Squibb

MG-JP-RCO-JRCT@bms.com+81-120-093-507

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026